FDA Reviews Trexima for Treatment of Migraines

Pharmacy Times
Volume 0

GlaxoSmithKline and POZEN Inc announced that the drugTrexima will be reviewed by the FDA for the acute treatmentof migraine headaches. The companies have proposed Treximaas the brand name for their combination of sumatriptansuccinate (Imitrex) and naproxen sodium (Aleve, for example)in a single-tablet form. Pending approval by the FDA, Treximacould be available to the public by the second half of 2006.

Ms. Farley is a freelance medical writer based in Wakefield, RI.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.